Advancing Gene-Targeted Therapies for Central Nervous System Disorders

A Workshop

April 23rd - 24th
Washington, DC
Workshop Planning Committee

Story Landis, Co-Chair, Forum on Neuroscience and Nervous System Disorders, workshop co-chair
Lamya Shihabuddin, Sanofi R&D, workshop co-chair
Zeshan (Shanny) Ahmed, Eli Lilly and Company
David Bredt, Janssen R&D
Daniel Burch, PPD Biotech
Joseph Buxbaum, Icahn School of Medicine at Mount Sinai
Beverly Davidson, Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine
Joshua Gordon, National Institute of Mental Health
Frances Jensen, University of Pennsylvania School of Medicine
John Krystal, Yale University School of Medicine
Maryann Redford, National Eye Institute
Todd Sherer, Michael J. Fox Foundation for Parkinson’s Research
Hao Wang, Takeda
Clinton Wright, National Institute of Neurological Disorders and Stroke
Workshop Objectives

Bring together experts and key stakeholders from academia, government, industry, and non-profit organizations to explore approaches for advancing the development of gene-targeted therapies for CNS disorders, including approaches that target nucleic acids, such as AAVs, ASOs, and RNAi, as well as gene product-targeted therapies.

- Provide an overview of the current landscape
- Discuss lessons learned from recent advances in gene therapy and ASO development
- Compare features of different gene-targeted therapy approaches, and discuss approaches to matching the approach to specific diseases, addressing their respective administration, distribution, and dose challenges, and potential long-term effects
- Explore clinical development and the regulatory pathway
- Discuss what it would take to move beyond rare genetic disorders
- Explore opportunities for catalyzing development of gene-targeted therapy
Agenda Overview

April 23

**Session I:** Current Landscape and Lessons Learned

**Session II:** Selecting Gene-Targeted Therapy Approaches for CNS Disorders

**Day One Closing Talk:** The Vista for Developing Gene-Targeting Therapies for Psychiatric and Other Circuit Disorders

April 24

**Session III:** Gene-Targeting Therapy Technologies for CNS Disorders

**Session IV:** Clinical Trial Design and Regulatory Pathways

**Session V:** Moving Forward